Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc > Oppenheimer report on Acasti, outperform, target US $6

<< Previous

Bullboard Posts

Next >>

Comment by flush777on Jan 05, 2022 1:51pm

379 Views

Post# 34286028

RE:Oppenheimer report on Acasti, outperform, target US $6

ok, the issuance of the report triggered a rush to a high of $2.30 on Dec 22, 2021. I guess that the whole world knows of the report ... except that it takes time for analysis and thoughts and yes, I do believe that the stock is a good buy and I purchased after the stock fell from $2,30 to its level prior to its rise.

Here is a chart of the day high/low/close from Dec 21-24, fyi.

Close Prices Last 3 Months